A Multicentre Study on Rifaximin in Post-operative Endoscopic Crohn's Disease Recurrence Prevention

Stopped The decision to prematurely close the trial recruitment period was taken due to the difficulties in the recruitment of patients. This decision has not been triggered by any unexpected safety signals identified during the study conduction.

Conditions

• Crohn Disease

Interventions

• DRUG: Rifaximin delayed release tablets
• OTHER: Placebo

Sponsor

Alfasigma S.p.A.

Collaborators

• [object Object]